XWELL (XWEL) Risk Assessment

View and export this data going back to 2010. Start your Free Trial

What is XWELL Risk Assessment?

Risk Assessment represents the investment risk of a stock derived from our exclusive method. It suggests how risky the investment opportunity is based on the valuation and the fundamental performance of the stock. It is derived from following key aspects:

1. GuruFocus internally developed valuations of the stock, such as GF valuation.
2. Quality Rank, a business quality indicator developed by GuruFocus.
3. Fundamental performance: Piotroski F-Score, Altman Z-Score, Beneish M-Score, etc.
4. Growth opportunities: 5-year revenue growth rate, 5-Year EPS without NRI Growth Rate, etc.

Value investors are always willing to find undervalued stocks. However, not all the undervalued stocks are good deals, we should also be careful of how risky the investment opportunity is. We believe that if the company's financial strength and profitability are strong, and the stock price is within a reasonable range of the GF valuation, or stock has a high return with its price being undervalued, then it might be a good investment opportunity with low risk.

Based on those aspects listed above, GuruFocus believes the risk assessment of XWELL is: High Risk: High uncertainty.

Competitive Comparison of XWELL's Risk Assessment

For the Diagnostics & Research subindustry, XWELL's Risk Assessment, along with its competitors' market caps and Risk Assessment data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

XWELL's Risk Assessment Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, XWELL's Risk Assessment distribution charts can be found below:

* The bar in red indicates where XWELL's Risk Assessment falls into.

XWELL (NAS:XWEL) Risk Assessment Explanation

Based on the four aspects listed above, GuruFocus provides the following 7 evaluations:

All-in-One Screener Examples (1)
Low Risk: Strong fundamentals, worth long-term holding
Moderate Risk: Sensitive, better choose undervalued stock
High Risk: High uncertainty with risk-return tradeoff
High Risk: Good fundamentals, beware of shrinking business
High Risk: Sensitive to economic or industry trends
High Risk: High uncertainty
No Data: Cannot be evaluated

(1) These are some simple examples. You can access our Risk Assessment filter under All-in-One Screener’s Fundamental tab and set your own criteria.

XWELL Risk Assessment Related Terms

Thank you for viewing the detailed overview of XWELL's Risk Assessment provided by GuruFocus.com. Please click on the following links to see related term pages.

XWELL (XWEL) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » XWELL Inc (NAS:XWEL) » Definitions » Risk Assessment

Comparable Companies

Traded in Other Exchanges

N/A

Address

254 West 31st Street, 11th Floor, New York, NY, USA, 10001

Website

https://www.xwell.com

XWELL Inc is a health and wellness holding company. It is an airport retailer of spa services through XpresSpa locations, offering travelers premium spa services, including massage, nail, and skincare, as well as spa and travel products. It operates four reportable operating segments: XpresCheck, XpresSpa, Treat, and HyperPointe. XpresSpa is an airport retailer of wellness services and related products. Treat is a travel health and wellness brand that offers in-airport spa and wellness medical services. XpresCheck provides Covid-19 screening and diagnostic testing in partnership with the CDC. HyperPointe is a digital healthcare and data analytics relationship company.

Executives

Suzanne A. Scrabis	officer: Chief Financial Officer	C/O XWELL, INC., 254 WEST 31ST STREET, 11TH FLOOR, NEW YORK NY 10001
Robert Weinstein	director	3960 HOWARD HUGHES PARKWAY, SUITE 500, LAS VEGAS NV 89169
Scott R Milford	officer: Chief Executive Officer	C/O TOWN SPORTS INTERNATIONAL, LLC, 5 PENN PLAZA, NEW YORK NY 10001
Bruce Bernstein	director	780 THIRD AVENUE, 12TH FLOOR, NEW YORK NY 10017
Ezra Ernst	officer: See Remarks	C/O XPRESSPA GROUP, INC., 254 WEST 31ST STREET, 11TH FLOOR, NEW YORK NY 10001
Omar Haynes	officer: VP Treas & Fi & Interim CFO	C/O XPRESSPA GROUP, INC., 254 WEST 31ST STREET, 11TH FLOOR, NEW YORK NY 10001
Doug Satzman	director, officer: Chief Executive Officer	780 THIRD AVENUE, 12TH FLOOR, NEW YORK NY 10017
James A. Berry	officer: Chief Financial Officer	C/O XPRESSPA GROUP, INC., 254 WEST 31ST STREET, 11TH FLOOR, NEW YORK NY 10001
Michael Lebowitz	director	780 THIRD AVENUE, 12TH FLOOR, C/O XPRESSPA GROUP, INC., NEW YORK NY 10017
Donald E. Stout	director	780 THIRD AVENUE, 15TH FLOOR, NEW YORK NY 10017
Mistral Spa Holdings, Llc	10 percent owner	C/O MISTRAL CAPITAL MANAGEMENT, LLC, 650 FIFTH AVENUE, 31ST FLOOR, NEW YORK NY 10019
Mistral Capital Management, Llc	10 percent owner	650 FIFTH AVENUE, 31ST FLOOR, NEW YORK NY 10019
Andrew R Heyer	other: Former director and 10% owner	501 MADISON AVENUE, FLOOR 5, NEW YORK NY 10019
Calm.com, Inc.	10 percent owner	140 2ND STREET, THIRD FLOOR, SAN FRANCISCO CA 94105
Edward Jankowski	officer: SVP; CEO of XpresSpa	C/O FORM HOLDINGS CORP., 780 THIRD AVENUE, 12TH FLOOR, NEW YORK NY 10017